Boston Scientific Corporation research snapshot
BSX AI stock analysis reads Boston Scientific Corporation as a high-quality medical technology compounder that is going through a hard valuation reset after its July 29, 2026 second quarter report. The company beat its own revenue and EPS guidance in Q2 2026, but cut full-year 2026 guidance because of softer WATCHMAN and electrophysiology demand and announced a restructuring plan. At the August 2, 2026 data cutoff, BSX traded near $46.73, down about 56% from its 52-week high of $109.50, with an implied market capitalization of about $69.46 billion. The analysis is scenario-based rather than a fixed price prediction: the upside case needs WATCHMAN and electrophysiology demand to stabilize while cardiovascular and MedSurg growth continues, while the downside case is tied to further guidance cuts, procedure-volume risk, and a technical break below recent lows.
Current price
$46.73
Market cap
$69.46 billion
AI score
63 / 100
Rating
Quality medtech franchise, guidance reset watch
Trend status
Short-term rebound above the 50-day moving average but still below the 100-day and 200-day moving averages
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Boston Scientific sells mission-critical medical devices across cardiovascular, endoscopy, urology, neuromodulation, and related procedure categories, with recurring procedure demand. Q2 2026 net sales rose 7.5% reported and 7.0% organic to $5.442 billion. | High |
| Moat | The moat comes from clinical evidence, physician training, regulatory approvals, manufacturing quality, global sales scale, product breadth, and acquired technology platforms such as electrophysiology, stroke prevention, and now TAVR through the MiRus investment. | High |
| Management | Management delivered a Q2 beat and completed a $2 billion accelerated share repurchase, but the full-year guidance cut tied to WATCHMAN and electrophysiology headwinds raises the bar for credibility, restructuring execution, and the pending Penumbra acquisition. | Medium |
| Financial trend | TTM revenue is $21.00 billion, up 13.5%, with TTM net income of $3.67 billion. Q2 2026 adjusted EPS of $0.86 beat guidance, but full-year 2026 organic growth guidance was cut to 5% to 6% from about 7% to 8.5%. | High |
| Valuation | At $46.73 and a 2026 adjusted EPS guidance midpoint near $3.30, BSX trades near 14.2x forward adjusted EPS, about 18.9x trailing EPS, and near 20x trailing free cash flow, down sharply from its historical premium. | Medium |
| Technical trend | The chart shows a short-term rebound: price is above the 20-day and 50-day moving averages with RSI near 58, but remains far below the 100-day moving average near $54.48 and the 200-day moving average near $73.17. | Medium |
| Risk level | Main risks are WATCHMAN and electrophysiology demand weakness, another estimate reset, procedure slowdowns, product recalls, FDA or reimbursement setbacks, acquisition integration including Penumbra and MiRus, litigation, and elevated debt after acquisitions. | Medium-high |
| AI confidence | Data confidence is high for reported facts and low-to-medium for forward price paths because guidance, analyst targets, and technical feeds moved sharply after the July 29, 2026 report. | High data confidence |
| Investment certainty | BSX is a strong medtech business, but a buy decision needs evidence that the guidance reset is conservative, that WATCHMAN and electrophysiology demand stabilize, and that the stock can hold above the $42 to $44 support zone. | Medium |
BSX AI stock forecast
The BSX AI stock forecast uses scenario math around the $46.73 price reference, the company 2026 adjusted EPS guidance midpoint near $3.30, and a three-year earnings multiple framework. The audited model produced a bearish area near $45, a base area near $67, and a bullish area near $88 before any future capital allocation effects. Analysts polled by S&P Global average a $62.69 target with a median near $60.
$82 to $92
More likely if WATCHMAN and electrophysiology demand stabilize, MedSurg keeps mid-single-digit growth, the restructuring plan improves margins, the Penumbra and MiRus deals integrate well, and investors restore a higher earnings multiple.
$62 to $72
More likely if organic growth settles near the 5% to 6% guidance, adjusted EPS compounds in high single digits, restructuring costs stay contained, and the market values BSX near a high-teens forward earnings multiple.
$42 to $48
More likely if the guidance reset is followed by another cut, WATCHMAN and electrophysiology demand keeps falling, acquisition integration adds debt or write-downs, or BSX is re-rated toward a low-teens earnings multiple near the 52-week low of $42.20.
BSX AI technical analysis
BSX AI technical analysis is mixed as of the August 2, 2026 data cutoff. The stock closed near $46.73 on July 31, 2026, above its 20-day and 50-day moving averages but well below the 100-day and 200-day moving averages. Barchart showed a 14-day RSI near 58.2, a 50-day moving average near $46.61, a 100-day moving average near $54.48, and a 200-day moving average near $73.17. This is a rebound within a longer downtrend, not a confirmed reversal.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $46.73 | StockAnalysis.com July 31, 2026 close, with a day range of $44.43 to $46.80. |
| Immediate support | $44.40 to $44.60 | The July 31 low was near $44.43 and the 20-day moving average sits near $44.58, forming the first support zone. |
| Secondary support | $42.20 to $43.00 | The 52-week low is near $42.20. A break below this zone would reset the rebound framework. |
| Near resistance | $54.00 to $55.00 | The 100-day moving average is near $54.48, with minor overhead near the $50 round level. This is the first meaningful upside test. |
| Major resistance | $73.00 to $74.00 | The 200-day moving average is near $73.17, a level the stock has traded below for months. |
| Moving averages | 50-day near $46.61, 100-day near $54.48, 200-day near $73.17 | Barchart showed price above the 50-day moving average but below the 100-day and 200-day moving averages. |
| Momentum | RSI near 58.2 | The Barchart 14-day RSI near 58.2 suggests firm short-term momentum after the oversold bounce, while the 14-day stochastic %K near 82 shows the rebound is getting warm. |
| Volume and volatility | 18.7 million shares on July 31, near the 19 million 20-day average | StockAnalysis.com listed 20-day average volume near 18.7 million shares. Barchart showed 14-day historic volatility near 31% and 50-day near 40%, so swings remain wide. |
| Invalidation | Close below $44.40 | A close back below the 20-day moving average would weaken the rebound; a close below $42.20 would invalidate the short-term setup. |
BSX AI trading strategy
The BSX AI trading strategy below is a rules-based research framework, not personal advice. It links Boston Scientific fundamentals, the July 29, 2026 guidance reset, medtech peer action, and technical confirmation with predefined invalidation levels.
Watch for BSX to reclaim and hold the $54 to $55 zone near the 100-day moving average, which would be the first sign the rebound is becoming a trend. Confirmation should come with stronger volume, stable guidance, and no new product or regulatory setback.
A failed move back below $44.40 after testing higher levels should reduce setup confidence because it would show supply still dominates.
If BSX retests the $42.20 to $44.50 zone without another guidance cut or device-risk disclosure, compare the reaction with medtech peers, analyst revisions, WATCHMAN and electrophysiology commentary, and cardiovascular segment data.
Do not treat the pullback as benign if price closes below $42.20 or if management lowers expectations again.
Track Q3 2026 sales growth, adjusted EPS, WATCHMAN and electrophysiology demand, MedSurg and Cardiovascular growth, gross margin, operating margin, free cash flow, restructuring charges, Penumbra and MiRus integration, and debt levels.
Position sizing should reflect medical-device regulatory risk, product-liability risk, reimbursement pressure, acquisition integration risk, and the volatility after the guidance reset.
Investment research summary
Boston Scientific sells specialized medical devices that help physicians treat complex cardiovascular, digestive, urological, neurological, respiratory, and oncological conditions. Customers pay because hospitals and physicians need reliable devices with clinical evidence and procedural support.
The moat is strongest in physician training, regulatory approvals, clinical data, product breadth, supply reliability, global commercial scale, and switching friction inside procedure workflows. It is weaker where competitors can copy features or compete on price, and the WATCHMAN and electrophysiology volume slowdown shows that even strong platforms face demand risk.
The thesis fails if WATCHMAN and electrophysiology demand keep falling, the restructuring plan fails to restore growth, acquisitions such as Penumbra and MiRus add debt or write-downs, or investors decide the company deserves a much lower medtech multiple.
Management delivered a Q2 beat, completed a $2 billion accelerated share repurchase, and moved into TAVR through the MiRus investment, but the full-year guidance cut is the key test. The question is whether the reset is conservative or the start of a longer slowdown.
The long-term trend is favorable because aging populations, minimally invasive procedures, electrophysiology demand, stroke prevention, and chronic disease treatment expand medtech demand. The offset is heavy regulation, payer scrutiny, and category-specific volume swings.
At $46.73, BSX trades near 14x forward adjusted EPS based on the 2026 guidance midpoint, well below its historical premium. The margin of safety depends on whether the 5% to 6% organic growth guidance holds and whether WATCHMAN and electrophysiology demand stabilize.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price reference | $46.73 close on July 31, 2026, day range $44.43 to $46.80 | StockAnalysis.com and Barchart quote snapshots | July 31, 2026 |
| Market capitalization | $69.46 billion, verified as $46.73 x 1,486,400,000 implied shares | financial_rigor.py market cap verification and StockAnalysis.com | August 2, 2026 |
| Shares outstanding | 1.49 billion | StockAnalysis.com share statistics | August 1, 2026 |
| Q2 2026 net sales | $5.442 billion, up 7.5% reported and 7.0% organic | Boston Scientific Q2 2026 earnings release | July 29, 2026 |
| Q2 2026 adjusted EPS | $0.86, up from $0.75, above guidance of $0.82 to $0.84 | Boston Scientific Q2 2026 earnings release | July 29, 2026 |
| Q2 2026 GAAP results | $907 million net income, or $0.61 per diluted share | Boston Scientific Q2 2026 earnings release | July 29, 2026 |
| Q2 2026 segment sales | MedSurg $1,818 million, Cardiovascular $3,624 million | Boston Scientific Q2 2026 earnings release | July 29, 2026 |
| Q2 2026 regional growth | U.S. +6.2%, EMEA +4.2% operational, APAC +11.2%, LACA +16.2% operational | Boston Scientific Q2 2026 earnings release | July 29, 2026 |
| FY2026 guidance | Reported sales growth 5.5% to 6.5%, organic 5% to 6%, adjusted EPS $3.28 to $3.32 | Boston Scientific Q2 2026 earnings release | July 29, 2026 |
| Q3 2026 guidance | Net sales growth about 3% to 5%, adjusted EPS $0.80 to $0.82 | Boston Scientific Q2 2026 earnings release | July 29, 2026 |
| Capital returns and deals | $2 billion ASR completed at about 40 million shares; $1.5 billion MiRus investment for about a 34% equity stake | Boston Scientific Q2 2026 earnings release | July 29, 2026 |
| FY2025 revenue | $20.074 billion, up 19.87% | StockAnalysis.com financials, Fiscal.ai data | August 1, 2026 |
| TTM financials | Revenue $21.00 billion, net income $3.67 billion, EPS $2.47 | StockAnalysis.com statistics | August 1, 2026 |
| Balance sheet | Cash and investments $1.45 billion, total debt $11.03 billion, net debt about -$9.58 billion | StockAnalysis.com statistics | August 1, 2026 |
| Valuation check | PE 18.93, forward PE 14.17, PS 3.31, PB 2.69, P/FCF 19.99, EV/EBITDA 19.04 | StockAnalysis.com statistics | August 1, 2026 |
| Analyst consensus | Buy with an average target of $62.69 across 31 analysts, low $44, median $60, high $94 | StockAnalysis.com forecast and analyst ratings | July 31, 2026 |
| Analyst rating mix, July 2026 | 19 Strong Buy, 8 Buy, 4 Hold out of 31 analysts | StockAnalysis.com recommendation trends | July 31, 2026 |
| Recent analyst target updates | Argus downgrade to Hold; JPMorgan $80 to $56, Evercore ISI $65 to $55, Deutsche Bank $75 to $60, RBC $85 to $70, UBS $74 to $67 | StockAnalysis.com latest forecasts and TipRanks | July 31, 2026 |
| Technical snapshot | 50-day SMA near $46.61, 100-day near $54.48, 200-day near $73.17, RSI near 58.2 | Barchart and StockAnalysis.com technical snapshots | July 31, 2026 |
| Short interest | 28.28 million shares short, 1.90% of shares outstanding, 1.42 days to cover | StockAnalysis.com statistics short selling | August 1, 2026 |
This BSX AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast scenarios are based on available public data as of August 2, 2026 and can be wrong if earnings, guidance, regulation, medical-device safety, reimbursement, interest rates, acquisition integration, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
